EZH2 and cancer: In vitro and in vivo trials have confirmed that GSK126, an EZH2 inhibitor, rescues the expression of downregulated genes in MLL3 knockdown cells, indicating that EZH2 represents a potential therapeutic target for MLL3 mutant cancers [133].